Additionally, pretreatment levels of ApoA1 are predicting favorable outcomes in patients undergoing anti-PD1 therapy for metastatic colorectal cancer, intrahepatic cholangiocarcinoma, and nasopharyngeal carcinoma (43–45). The gene discussed is APOA1; the disease is nasopharyngeal carcinoma.